Orbit Discovery
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Orbit Discovery develops and applies drug-discovery platforms centered on a peptide display engine that yields novel, biologically relevant peptide leads. The engine can target cell-based contexts, enabling screening in environments that reflect how targets behave in biology. The company was founded in late 2015 as a spin-out from Oxford University, drawing on the work of Professors Graham Ogg and Terry Rabbitts. Based in Oxford, Oxfordshire, England, Orbit Discovery operates in the biotechnology research sector and maintains a pipeline of novel targets pursued through internal programmes and collaborations. Its peptide leads are considered starting points for developing peptide therapeutics, peptidomimetics, small molecules and bioconjugates used for cell targeting and cargo delivery. In September 2023, Orbit Discovery announced a collaboration with Orano Med SAS to develop peptide receptor radionuclide therapies for cancer and to advance radiopharmaceuticals.
1-888-653-2347 
support@leadiq.com 
